Biological effects of Cs-137 and X-ray irradiators are comparable with regards to reconstitution chimerism in normal and autoimmune settings.

Spectral Instruments Imaging provides unrivaled sensitivity for bioluminescence, fluorescence and X-Ray for in vivo imaging analysis.

Transdermal skin delivery is a method to transport various topical formulations to a deeper skin layer non-invasively. However, it cannot reveal a detailed depth-dependent distribution profile of transdermally delivered agents in the skin.

This is the first of a 4-part series introducing Scintica’s newly formed relationship with IVIM Technology and their IntraVital Microscopy platform (IVM).

Intravital microscopy can visualize various in vivo cellular-level dynamics such as cell trafficking, cell-to-cell or cell-to-microenvironment interactions in a living animal. Intravital imaging of pathophysiological cellular dynamics in natural in vivo microenvironment in various preclinical animal model can provide an unprecedented insight in the dynamic processes of human diseases beyond conventional histological observation of ex vivo sample or in vitro culture sample.

Intravital microscopy can visualize various in vivo cellular-level dynamics such as cell trafficking, cell-to-cell or cell-to-microenvironment interactions in a living animal. Intravital imaging of pathophysiological cellular dynamics in natural in vivo microenvironment in various preclinical animal model can provide an unprecedented insight in the dynamic processes of human diseases beyond conventional histological observation of ex vivo sample or in vitro culture sample.

Highlighting bioluminescent imaging in Oncology applications with Dr. Michael Henry, Professor of department of Molecular Physiology & Biophysics, University of Iowa Carver College of Medicine.

Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin’s lymphoma. BEZ235 is an effective dual PI3K/mTOR inhibitor, but it was withdrawn from early-phase clinical trials owing to poor solubility and on-target/off-tumor toxicity.

This work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC, and suggests that NSD3-dependency renders LUSC therapeutically vulnerable to bromodomain inhibition.